FlyGear, a robotic device for monitoring insects automatically and accurately
- Details
- Category: Technological offers
-
15 Jun 2022

The CSIC and the Miguel Hernández University have developed a robot and its software for counting and measuring, in an automated, precise and reliable way, the transition time between life stages of fruit flies and other insects.
A biomarker signature for predicting response to cancer immunotherapy
- Details
- Category: Technological offers
-
05 May 2022

The CSIC has developed, together with other institutions, a method to personalise therapeutic strategies combined with immune checkpoint inhibitors (ICIs) in cancer patients. It is based on 10 biomarkers, and facilitates the optimisation of therapeutic strategies for various types of tumours.
Miniaturized device for electrical stimulation of cell cultures
- Details
- Category: Technological offers
-
02 Mar 2022

The use of electrical stimulation in medical research is growing rapidly for its effects on cell regeneration. The CSIC, the Autonomous University of Madrid and the University of Florida have developed a miniaturised device for in vitro electrical stimulation of cells and tissues. The technology is available for further development and commercialization.
Patented molecules that counteract the effect of the most common anticoagulant drug
- Details
- Category: Technological offers
-
16 Mar 2022

Researchers at IQAC-CSIC have successfully tested molecules that reverse the effect of the anticoagulant heparin, used to treat patients at risk of thrombosis. These new molecules have been patented. Patients treated with heparin may need to block its effect during surgery. The only drug available nowadays has a high molecular weight and may have associated side effects.
DNA probes for the fast detection of SARS-CoV2 and influenza virus
- Details
- Category: Technological offers
-
01 Mar 2022

Scientists from the CSIC, the University of Barcelona and the CIBER network laboratory have developed DNA probes for the fast detection of respiratory disease viruses, including SARS-CoV2 and influenza. The technology is available for further development through agreements with industry partners.